Status:
UNKNOWN
Curcuma Xanthorriza Roxb. 10% Cream for Melasma
Lead Sponsor:
Universitas Padjadjaran
Conditions:
Melasma
Eligibility:
All Genders
Phase:
EARLY_PHASE1
Brief Summary
Melasma is an acquired hyperpigmentation disorder with a multifactorial etiology and complex pathogenesis that can significantly diminish the quality of life for affected patients. As of now, melasma ...
Detailed Description
Curcuma xanthorrhiza Roxb., known locally as temulawak in Indonesia or koneng gede in Sundanese, is a member of the Zingiberaceae family and is native to Indonesia. Previous research related to Curcum...
Eligibility Criteria
Inclusion
- Females and males diagnosed with epidermal-type melasma clinically and through Wood's lamp examination.
- Study subjects exhibit melasma lesions on both sides of the face.
Exclusion
- History of hypersensitivity to Curcuma xanthorriza Roxb. or kojic acid based on anamnesis.
- Pregnant and breastfeeding women.
- Patients using hormonal contraceptive drugs in the last 3 months.
- Patients using topical medications (depigmentation agents, tretinoin, or corticosteroids) in the skin area to be tested in the last 2 weeks.
- Patients using systemic corticosteroids in the last 1 month.
- Patients undergoing laser therapy, microdermabrasion, chemical peels, and other aesthetic procedures in the skin area to be tested in the last 1 month.
- Patients experiencing inflammation on the facial skin.
Key Trial Info
Start Date :
December 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 22 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06153134
Start Date
December 22 2023
End Date
May 22 2024
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hasan Sadikin General Hospital
Bandung, West Java, Indonesia, 40161